Affiliation:
1. Department of Pharmacology, Welsh School of Pharmacy, Cardiff University, Cathays Park, Cardiff CF10 3XF, UK
2. GlaxoSmithKline Laboratoires Pharmaceutiques, 4 rue du Chesnay-Beauregard, 3576 Saint-Grégoire, France
Abstract
Abstract
The hypothesis that the coronary vasodilator effects of adenosine receptor agonists are independent of the vascular endothelium or mediators derived therefrom was examined in guinea-pig isolated working hearts. Adenosine receptor agonists, 5′-(N-ethylcarboxamido)-adenosine (NECA; two-fold selective for A2 over A1 receptors), 2-[p-(2-carboxyethyl)phenylethylamino]-5′-N-ethylcarboxamidoadenosine (CGS21680; A2A selective), N6-cyclopentyl-adenosine (CPA; A1 selective) and N6-(3-iodobenzyl)adenosine-5′-N-methyluronamide (IB-MECA; A3 selective), were infused (3 times 10−7 M) after endothelium removal by passing oxygen through the coronary circulation. In spontaneously beating hearts, CGS21680 and NECA increased, while CPA decreased, coronary flow. NECA and CPA reduced heart rate, left ventricular pressure and aortic output. The nitric oxide synthase (NOS) inhibitor, NG-nitro-L-arginine (L-NOARG; 3 times 10−5 M) abolished the vasodilatation by NECA but not CGS21680, indicating that nitric oxide (NO) of a non-endothelial source mediated the NECA response. Coronary vasodilatation by CGS21680 was inhibited by the A2A receptor antagonist, 4-(2-[7-amino-2-(2-furyl)[1,2,4]triazolo [2,3-a][1,3,5]triazin-5-ylamino]ethyl)phenol (ZM241385). Indometacin (10−6 M) attenuated the coronary vasodilatation to CGS21680, suggesting a partial role for cyclooxygenase products. IBMECA had no effect, indicating no A3 receptor involvement. In paced working hearts, the responses were similar except CPA had no effect on coronary flow or aortic output and CGS21680 increased left ventricular pressure and the maximum rate of ventricular pressure rise. This study has demonstrated functionally effective removal of the endothelium by a novel method of passing oxygen through the coronary vasculature. A coronary vasodilator action of adenosine receptor agonists mediated via A2A receptors is endothelium-and NO-independent, but partially involves cyclooxygenase products.
Publisher
Oxford University Press (OUP)
Subject
Pharmaceutical Science,Pharmacology
Reference40 articles.
1. Differential antagonism by 1,3-dipropylxanthine-8-cyclo-pentylxanthine and 9-chloro-2-(2-furanyl)-5,6-dihydro-12,4-triazolo(1,5-c)quinazolin-5-imineof the effects of adenosine derivatives in the presence of isoprenaline on contractile response and cyclic AMP content in myocytes. Evidence for the coexistence of A1- and A2-adenosine receptors on cardiomyocytes;Behnke;J. Pharmacol Exp. Ther.,1990
2. The cardiac effects of adenosine;Bellardinelli;Prog. Cardiovasc. Dis.,1989
3. The A2a adenosine receptor mediates coronary vasodilatation;Bellardinelli;J. Pharmacol. Exp. Ther.,1998
4. Adenosine inhibits neutrophil degranulation in activated human whole blood;Bouma;J. Immunol.,1997
5. P1-purinoceptor-mediated vasodilatation and vasoconstriction in hypoxia;Broadley;J. Auton. Pharmacol.,1996
Cited by
17 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献